Skip to main content
Top
Published in: BMC Cancer 1/2010

Open Access 01-12-2010 | Research article

Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer

Authors: Sandra Waalkes, Faranaz Atschekzei, Mario W Kramer, Jörg Hennenlotter, Gesa Vetter, Jan U Becker, Arnulf Stenzl, Axel S Merseburger, Andres J Schrader, Markus A Kuczyk, Jürgen Serth

Published in: BMC Cancer | Issue 1/2010

Login to get access

Abstract

Background

Fibronectin 1 (FN1) is a glycoprotein involved in cellular adhesion and migration processes. The aim of this study was to elucidate the role of FN1 in development of renal cell cancer (RCC) and to determine a prognostic relevance for optimal clinical management.

Methods

212 renal tissue samples (109 RCC, 86 corresponding tissues from adjacent normal renal tissue and 17 oncocytomas) were collected from patients undergoing surgery for renal tumors and subjected to total RNA extraction. Detection of FN1 mRNA expression was performed using quantitative real time PCR, three endogenous controls, renal proximal tubular epithelial cells (RPTEC) as biological control and the ΔΔCt method for calculation of relative quantities.

Results

Mean tissue specific FN1 mRNA expression was found to be increased approximately seven fold comparing RCC and corresponding kidney control tissues (p < 0.001; ANOVA). Furthermore, tissue specific mean FN1 expression was increased approx. 11 fold in clear cell compared to papillary RCC (p = 9×10-5; Wilcoxon rank sum test). Patients with advanced disease had higher FN1 expression when compared to organ-confined disease (p < 0.001; Wilcoxon rank sum test). Applying subgroup analysis we found a significantly higher FN1 mRNA expression between organ-confined and advanced disease in the papillary and not in the clear cell RCC group (p = 0.02 vs. p = 0.2; Wilcoxon rank sum test). There was an increased expression in RCC compared to oncocytoma (p = 0.016; ANOVA).

Conclusions

To our knowledge, this is the first study to show that FN1 mRNA expression is higher in RCC compared to normal renal tissue. FN1 mRNA expression might serve as a marker for RCC aggressiveness, indicating early systemic progression particularly for patients with papillary RCC.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schrader AJ, Rustemeier J, Rustemeier JC, Timmesfeld N, Varga Z, Hegele A, Olbert PJ, Hofmann R: Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma. J Cancer Res Clin Oncol. 2009, 135: 1693-1699. 10.1007/s00432-009-0616-2.CrossRefPubMed Schrader AJ, Rustemeier J, Rustemeier JC, Timmesfeld N, Varga Z, Hegele A, Olbert PJ, Hofmann R: Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma. J Cancer Res Clin Oncol. 2009, 135: 1693-1699. 10.1007/s00432-009-0616-2.CrossRefPubMed
2.
go back to reference Schrader AJ, Sevinc S, Olbert PJ, Hegele A, Varga Z, Hofmann R: [Gender-specific characteristics and survival of renal cell carcinoma]. Urologe A. 2008, 47 (1182): 1184-1186. Schrader AJ, Sevinc S, Olbert PJ, Hegele A, Varga Z, Hofmann R: [Gender-specific characteristics and survival of renal cell carcinoma]. Urologe A. 2008, 47 (1182): 1184-1186.
3.
go back to reference Wilson CB, Leopard J, Cheresh DA, Nakamura RM: Extracellular matrix and integrin composition of the normal bladder wall. World J Urol. 1996, 14 (Suppl 1): S30-37.PubMed Wilson CB, Leopard J, Cheresh DA, Nakamura RM: Extracellular matrix and integrin composition of the normal bladder wall. World J Urol. 1996, 14 (Suppl 1): S30-37.PubMed
4.
go back to reference Akiyama SK, Olden K, Yamada KM: Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev. 1995, 14: 173-189. 10.1007/BF00690290.CrossRefPubMed Akiyama SK, Olden K, Yamada KM: Fibronectin and integrins in invasion and metastasis. Cancer Metastasis Rev. 1995, 14: 173-189. 10.1007/BF00690290.CrossRefPubMed
5.
go back to reference Warawdekar UM, Zingde SM, Iyer KS, Jagannath P, Mehta AR, Mehta NG: Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patients. Clin Chim Acta. 2006, 372: 83-93. 10.1016/j.cca.2006.03.023.CrossRefPubMed Warawdekar UM, Zingde SM, Iyer KS, Jagannath P, Mehta AR, Mehta NG: Elevated levels and fragmented nature of cellular fibronectin in the plasma of gastrointestinal and head and neck cancer patients. Clin Chim Acta. 2006, 372: 83-93. 10.1016/j.cca.2006.03.023.CrossRefPubMed
6.
go back to reference Haglund C, Ylatupa S, Mertaniemi P, Partanen P: Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA. Br J Cancer. 1997, 76: 777-783.CrossRefPubMedPubMedCentral Haglund C, Ylatupa S, Mertaniemi P, Partanen P: Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA. Br J Cancer. 1997, 76: 777-783.CrossRefPubMedPubMedCentral
7.
go back to reference Torbenson M, Wang J, Choti M, Ashfaq R, Maitra A, Wilentz RE, Boitnott J: Hepatocellular carcinomas show abnormal expression of fibronectin protein. Mod Pathol. 2002, 15: 826-830. 10.1097/01.MP.0000024257.83046.7C.CrossRefPubMed Torbenson M, Wang J, Choti M, Ashfaq R, Maitra A, Wilentz RE, Boitnott J: Hepatocellular carcinomas show abnormal expression of fibronectin protein. Mod Pathol. 2002, 15: 826-830. 10.1097/01.MP.0000024257.83046.7C.CrossRefPubMed
8.
go back to reference Ylatupa S, Haglund C, Mertaniemi P, Vahtera E, Partanen P: Cellular fibronectin in serum and plasma: a potential new tumour marker?. Br J Cancer. 1995, 71: 578-582.CrossRefPubMedPubMedCentral Ylatupa S, Haglund C, Mertaniemi P, Vahtera E, Partanen P: Cellular fibronectin in serum and plasma: a potential new tumour marker?. Br J Cancer. 1995, 71: 578-582.CrossRefPubMedPubMedCentral
9.
go back to reference Cho J, Mosher DF: Role of fibronectin assembly in platelet thrombus formation. J Thromb Haemost. 2006, 4: 1461-1469. 10.1111/j.1538-7836.2006.01943.x.CrossRefPubMed Cho J, Mosher DF: Role of fibronectin assembly in platelet thrombus formation. J Thromb Haemost. 2006, 4: 1461-1469. 10.1111/j.1538-7836.2006.01943.x.CrossRefPubMed
10.
go back to reference Mosher DF: Plasma fibronectin concentration: a risk factor for arterial thrombosis?. Arterioscler Thromb Vasc Biol. 2006, 26: 1193-1195. 10.1161/01.ATV.0000223342.15969.7a.CrossRefPubMed Mosher DF: Plasma fibronectin concentration: a risk factor for arterial thrombosis?. Arterioscler Thromb Vasc Biol. 2006, 26: 1193-1195. 10.1161/01.ATV.0000223342.15969.7a.CrossRefPubMed
11.
go back to reference Orem C, Celik S, Orem A, Calapoglu M, Erdol C: Increased plasma fibronectin levels in patients with acute myocardial infarction complicated with left ventricular thrombus. Thromb Res. 2002, 105: 37-41. 10.1016/S0049-3848(01)00414-5.CrossRefPubMed Orem C, Celik S, Orem A, Calapoglu M, Erdol C: Increased plasma fibronectin levels in patients with acute myocardial infarction complicated with left ventricular thrombus. Thromb Res. 2002, 105: 37-41. 10.1016/S0049-3848(01)00414-5.CrossRefPubMed
12.
go back to reference Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, Novick A: TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997, 80 (5): 992-993. 10.1002/(SICI)1097-0142(19970901)80:5<992::AID-CNCR26>3.0.CO;2-Q.CrossRefPubMed Guinan P, Sobin LH, Algaba F, Badellino F, Kameyama S, MacLennan G, Novick A: TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997, 80 (5): 992-993. 10.1002/(SICI)1097-0142(19970901)80:5<992::AID-CNCR26>3.0.CO;2-Q.CrossRefPubMed
13.
go back to reference Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. The American journal of surgical pathology. 1982, 6 (7): 655-663. 10.1097/00000478-198210000-00007.CrossRefPubMed Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. The American journal of surgical pathology. 1982, 6 (7): 655-663. 10.1097/00000478-198210000-00007.CrossRefPubMed
14.
go back to reference Stenzl A, deKernion JB: Pathology, biology, and clinical staging of renal cell carcinoma. Seminars in oncology. 1989, 16 (1 Suppl 1): 3-11.PubMed Stenzl A, deKernion JB: Pathology, biology, and clinical staging of renal cell carcinoma. Seminars in oncology. 1989, 16 (1 Suppl 1): 3-11.PubMed
15.
go back to reference Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73.CrossRefPubMed Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008, 3: 1101-1108. 10.1038/nprot.2008.73.CrossRefPubMed
16.
go back to reference Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.CrossRefPubMed
18.
go back to reference de la Fuente MT, Casanova B, Garcia-Gila M, Silva A, Garcia-Pardo A: Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia. 1999, 13: 266-274. 10.1038/sj.leu.2401275.CrossRefPubMed de la Fuente MT, Casanova B, Garcia-Gila M, Silva A, Garcia-Pardo A: Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia. 1999, 13: 266-274. 10.1038/sj.leu.2401275.CrossRefPubMed
19.
go back to reference Wolf M, El-Rifai W, Tarkkanen M, Kononen J, Serra M, Eriksen EF, Elomaa I, Kallioniemi A, Kallioniemi OP, Knuutila S: Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet Cytogenet. 2000, 123: 128-132. 10.1016/S0165-4608(00)00319-8.CrossRefPubMed Wolf M, El-Rifai W, Tarkkanen M, Kononen J, Serra M, Eriksen EF, Elomaa I, Kallioniemi A, Kallioniemi OP, Knuutila S: Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genet Cytogenet. 2000, 123: 128-132. 10.1016/S0165-4608(00)00319-8.CrossRefPubMed
20.
go back to reference Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP, Kononen J: Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 2000, 60: 6617-6622.PubMed Sallinen SL, Sallinen PK, Haapasalo HK, Helin HJ, Helen PT, Schraml P, Kallioniemi OP, Kononen J: Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res. 2000, 60: 6617-6622.PubMed
21.
go back to reference Chen M, Marinkovich MP, Jones JC, O'Toole EA, Li YY, Woodley DT: NC1 domain of type VII collagen binds to the beta3 chain of laminin 5 via a unique subdomain within the fibronectin-like repeats. J Invest Dermatol. 1999, 112: 177-183. 10.1046/j.1523-1747.1999.00491.x.CrossRefPubMed Chen M, Marinkovich MP, Jones JC, O'Toole EA, Li YY, Woodley DT: NC1 domain of type VII collagen binds to the beta3 chain of laminin 5 via a unique subdomain within the fibronectin-like repeats. J Invest Dermatol. 1999, 112: 177-183. 10.1046/j.1523-1747.1999.00491.x.CrossRefPubMed
22.
go back to reference Takayasu H, Horie H, Hiyama E, Matsunaga T, Hayashi Y, Watanabe Y, Suita S, Kaneko M, Sasaki F, Hashizume K, et al: Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res. 2001, 7: 901-908.PubMed Takayasu H, Horie H, Hiyama E, Matsunaga T, Hayashi Y, Watanabe Y, Suita S, Kaneko M, Sasaki F, Hashizume K, et al: Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res. 2001, 7: 901-908.PubMed
23.
go back to reference Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila S: Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet. 2001, 128: 1-6. 10.1016/S0165-4608(01)00386-7.CrossRefPubMed Tapper J, Kettunen E, El-Rifai W, Seppala M, Andersson LC, Knuutila S: Changes in gene expression during progression of ovarian carcinoma. Cancer Genet Cytogenet. 2001, 128: 1-6. 10.1016/S0165-4608(01)00386-7.CrossRefPubMed
24.
go back to reference Schrader AJ, Rauer-Bruening S, Olbert PJ, Hegele A, Rustemeier J, Timmesfeld N, Varga Z, Hofmann R: Incidence and long-term prognosis of papillary renal cell carcinoma. J Cancer Res Clin Oncol. 2009, 135: 799-805. 10.1007/s00432-008-0515-y.CrossRefPubMed Schrader AJ, Rauer-Bruening S, Olbert PJ, Hegele A, Rustemeier J, Timmesfeld N, Varga Z, Hofmann R: Incidence and long-term prognosis of papillary renal cell carcinoma. J Cancer Res Clin Oncol. 2009, 135: 799-805. 10.1007/s00432-008-0515-y.CrossRefPubMed
25.
go back to reference Brenner W, Gross S, Steinbach F, Horn S, Hohenfellner R, Thuroff JW: Differential inhibition of renal cancer cell invasion mediated by fibronectin, collagen IV and laminin. Cancer Lett. 2000, 155: 199-205. 10.1016/S0304-3835(00)00429-8.CrossRefPubMed Brenner W, Gross S, Steinbach F, Horn S, Hohenfellner R, Thuroff JW: Differential inhibition of renal cancer cell invasion mediated by fibronectin, collagen IV and laminin. Cancer Lett. 2000, 155: 199-205. 10.1016/S0304-3835(00)00429-8.CrossRefPubMed
26.
go back to reference Lohi J, Tani T, Leivo I, Linnala A, Kangas L, Burgeson RE, Lehto VP, Virtanen I: Expression of laminin in renal-cell carcinomas, renal-cell carcinoma cell lines and xenografts in nude mice. Int J Cancer. 1996, 68: 364-371. 10.1002/(SICI)1097-0215(19961104)68:3<364::AID-IJC15>3.0.CO;2-8.CrossRefPubMed Lohi J, Tani T, Leivo I, Linnala A, Kangas L, Burgeson RE, Lehto VP, Virtanen I: Expression of laminin in renal-cell carcinomas, renal-cell carcinoma cell lines and xenografts in nude mice. Int J Cancer. 1996, 68: 364-371. 10.1002/(SICI)1097-0215(19961104)68:3<364::AID-IJC15>3.0.CO;2-8.CrossRefPubMed
27.
go back to reference Murata J, Saiki I, Yoneda J, Azuma I: Differences in chemotaxis to fibronectin in weakly and highly metastatic tumor cells. Jpn J Cancer Res. 1992, 83: 1327-1333.CrossRefPubMed Murata J, Saiki I, Yoneda J, Azuma I: Differences in chemotaxis to fibronectin in weakly and highly metastatic tumor cells. Jpn J Cancer Res. 1992, 83: 1327-1333.CrossRefPubMed
28.
go back to reference Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, et al: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005, 23: 2763-2771. 10.1200/JCO.2005.07.055.CrossRefPubMed Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani W, Abbou CC, et al: Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005, 23: 2763-2771. 10.1200/JCO.2005.07.055.CrossRefPubMed
Metadata
Title
Fibronectin 1 mRNA expression correlates with advanced disease in renal cancer
Authors
Sandra Waalkes
Faranaz Atschekzei
Mario W Kramer
Jörg Hennenlotter
Gesa Vetter
Jan U Becker
Arnulf Stenzl
Axel S Merseburger
Andres J Schrader
Markus A Kuczyk
Jürgen Serth
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2010
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-10-503

Other articles of this Issue 1/2010

BMC Cancer 1/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine